Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025PharmaceuticsOpen Access

Strategic and Chemical Advances in Antibody–Drug Conjugates

View Full Paper
Ask AI
Bookmark
Share

Authors

IAIbrahim AlradwanMAMeshal K. AlnefaieNFNojoud AL Fayez

Discussion

Loading...

Member takes

Overview

Review examines antibody-drug conjugates' efficacy in cancer treatment, highlighting innovations in conjugation strategies and pharmacokinetics.

Key Points

  • Antibody-drug conjugates (ADCs) improve cancer treatment by targeting malignant cells while minimizing damage to normal tissues.
  • Over 200 ADCs are currently in clinical trials, showcasing substantial progress in their design and application for various cancer types.
  • Innovative conjugation strategies, including lysine and cysteine chemistries, enhance the homogeneity and stability of ADCs.
  • Novel ADC architectures aim to combat tumor heterogeneity and drug resistance, highlighting the need for regulatory harmonization.

Cite This Study

Alradwan et al. (2025) studied this question.

synapsesocial.com/papers/68c192579b7b07f3a0616fb1https://doi.org/10.3390/pharmaceutics17091164
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs2025 · 19 citations
  2. 2Advanced Antibody–Drug Conjugates Design: Innovation in Linker Chemistry and Site‐Specific Conjugation Technologies2025 · 31 citations
  3. 3Antibody–Drug Conjugates: Bridging Science and Therapeutics2025
  4. 4Advancing Antibody-Drug Conjugates: Current Perspectives and Future Directions2026 · 1 citations
  5. 5Recent advances in antibody–drug conjugates2026